Therefore, instead of directly targeting neoplastic MYC, our study theoretically justifies clinically approved PARP and ATM inhibitors that can be co-used to re-establish platinum sensitivity even in platinum-refractory cancer cells. This evidence concerns the gene PARP1 and cancer.